Date
12 July 2018
Despite looming resistance crisis, Novartis ducks out of antibiotics research
Phil Taylor of FierceBiotech reports on Novartis’ recent announcement to shut down its antibacterial and antiviral research programmes. The article refers to the findings of the Foundation’s AMR Benchmark, published in January 2018.
Direct links
“According to a recent report by the Access to Medicine Foundation (AMF), the multinational pharma companies’ retreat from the sector is a problem. While companies like GlaxoSmithKline, Johnson & Johnson and Pfizer are leading the charge, there is still not enough being done on an industrywide basis to avert a future healthcare crisis."